Why Choose PiaSky® (crovalimab) for PNH

Put your patients in control of their PNH treatment: a C5 inhibitor in a convenient subcutaneous injection1-3*

 

PiaSky® is the latest addition to the standard of PNH care.2,4

Product image
syringe-icon

PiaSky® : The only 4-weekly subcutaneous treatment for patients with PNH¹˒²˒⁵

PiaSky® gives patients an alternative to existing treatment options, without sacrificing the efficacy of an established class of therapies.⁶

hospital-icon

Quick subcutaneous injections at home or in the clinic

After initial IV infusion and loading doses, PiaSky® maintenance doses can be subcutaneously self-injected or given by a caregiver at home, reducing the burden on healthcare systems and providing more time to both physicians and patients with PNH.²˒⁵⁻⁷

Does the Chronic Nature of PNH Influence Treatment Decisions?- Dr. Austin Kulasekararaj

PiaSky® (crovalimab) is the preferred choice for people with PNH
Patients with PNH preferred PiaSky: 84–96% over eculizumab and 62% over ravulizumab, citing easier use, shorter treatment time, and better quality of life.

Across arms, the top reasons for PiaSky® preference included8:
Diagram showing the mechanism of action of PiaSky, it illustrates high-affinity C5 binding, inhibition of C5 cleavage, enhanced cellular uptake, pH-dependent antigen release, lysosomal degradation, and FcRn-mediated recycling - demonstrating improved antibody durability and complement inhibition efficacy.

Time to administer treatment was shorter

Diagram showing the mechanism of action of PiaSky, it illustrates high-affinity C5 binding, inhibition of C5 cleavage, enhanced cellular uptake, pH-dependent antigen release, lysosomal degradation, and FcRn-mediated recycling - demonstrating improved antibody durability and complement inhibition efficacy.

The way the treatment was given was easier

Diagram showing the mechanism of action of PiaSky, it illustrates high-affinity C5 binding, inhibition of C5 cleavage, enhanced cellular uptake, pH-dependent antigen release, lysosomal degradation, and FcRn-mediated recycling - demonstrating improved antibody durability and complement inhibition efficacy.

Better quality of life

PiaSky® enhances standard of care with innovative SMART-Ig recycling technology
PiaSky® recycling technology allows

PNH patients currently have a significant treatment burden11

People with PNH face many challenges:

PiaSky® can help alleviate the lifetime burden of PNH:

Many people live far from medical facilities12,13
 

Time, cost and support to travel to a healthcare facility can be excessive for people with PNH without access to transport


SC injection with the option to administer at home reduces travel costs and time spent travelling to the clinic1,4,13¶

Infusions are scheduled every 2 or 8 weeks14,15

Infusions and travel are time-consuming and can disrupt daily life11


SC is more efficient than IV administration, with less time spent at the clinic administering treatment7,16

Treatment generally continues for a lifetime17

Patients often present in their 30s or 40s, with decades of treatment ahead17,18


SC injection at home or in the clinic significantly reduces time spent in clinic over a lifetime compared with IV, and enables people with PNH the ability to operate a ‘normal’ lifestyle7,16,19,20

People treated with IV C5is still experience reduced quality of life8,21,22

Treatment satisfaction with IV C5is was low based on parameters such as ‘convenience’, with many people preferring a treatment with reduced treatment frequency and easier administration4,8,20


At-home SC administration easily fits around the patient’s schedule with minimal disruption to daily routine, improving convenience5,20

How does IV therapy impact the quality of life for PNH patients? - Prof. Dr. Alexander Röth

It’s time to give PNH patients their lives back

PiaSky® is available for C5i-naïve and C5i-experienced patients, with consistent efficacy and safety among both patient populations
icon-6

C5i-naïve and C5-experienced patients with PNH have the same underlying disease pathology and are not considered distinct populations²³

Learn more
icon-5

The efficacy of complement inhibition in C5i-experienced patients is expected to parallel results seen in C5i-naïve patients once hemolysis control has been achieved⁵˒⁶

Learn more
icon-4

The safety of PiaSky® is consistent among C5i-naïve and experienced patients, apart from the risk of TICRs in patients who switch between PiaSky® and other C5is⁵˒⁶

Learn more

*Patients starting PiaSky® will receive an initial weight-based loading dose through IV infusion, administered by their healthcare provider. Four subsequent loading doses are then given weekly by subcutaneous injection. Weight-based maintenance dosing is then administered once every 4 weeks subcutaneously. Patients may self-inject after receiving training from their healthcare provider.2
†Patients were assessed after 17 weeks of crovalimab, patients randomized to eculizumab who switched to PiaSky® in the extension period (n=38), only patients with available data (having completed the questionnaire) were included in the calculations of percentages. Questionnaire completion rate was 83%.8
‡Treatment preference among patients in COMMODORE 1 and 2 who were randomized to receive eculizumab (arm B) and switched to PiaSky® in the extension period.
§In COMMODORE 1, a non-randomized arm including patients previously treated with ravulizumab was not included in the randomized arm, patients were assessed after 17 weeks of crovalimab, patients who switched from ravulizumab to PiaSky® (n=15), only patients with available data (having completed the questionnaire) were included in the calculations of percentages. Questionnaire completion rate was 88%.9
PiaSky® treatment begins with a single IV weight-based loading dose administered in the clinic.
C5 = complement protein 5; IV=intravenous; IVH = intravascular hemolysis; PNH = paroxysmal nocturnal hemoglobinuria; SC = subcutaneous; SNP = single nucleotide polymorphism; TICR = transient immune complex reactions; wt = wildtype.

Get Resources

Find support for treating your patients with PiaSky®.

Learn more

PiaSky® Dosing

See how maintenance dosing once every 4 weeks may help your patients treat PNH on their terms.

Learn more
References
  1. Röth A, et al. Blood. 2020.
  2. PiaSky® (crovalimab) 170mg/mL solution for injection Summary of Product Characteristics. F-Hoffmann-La Roche; 2024.
  3. Overton P, et al. Patients Prefer Adherence. 2021;15:811–834.
  4. Bektas M, et al. J Manag Care Spec Pharm. 2020;26:S14–S20.
  5. Scheinberg P, et al. Am J Hematol. 2024;99:1757–1767.
  6. Röth A, et al. Am J Hematol. 2024;99:1768–1777.
  7. Bittner B, et al. BioDrugs. 2018;32:425–440.
  8. Kulasekararaj A, et al. EHA 2024; poster presentation [poster P839].
  9. Scheinberg P, et al. ASH 2024; poster presentation [abs p4078].
  10. Sampei Z, et al. Int J Mol Sci. 2024;25:11679.
  11. Ueda Y, et al. Ann Hematol. 2025;1–10.
  12. Weiss DJ, et al. Nat Med. 2020;26:1835–1838.
  13. Hirth W, et al. ISPOR 2024; poster presentation [poster OP7].
  14. Ultomiris™ (ravulizumab-cvwz) Prescribing Information. Boston MA: Alexion Pharmaceuticals, Inc; 2024.
  15. Soliris® (eculizumab) Prescribing information. Boston, MA: Alexion Pharmaceuticals, Inc; 2024.
  16. Heald A, et al. Int J Clin Pract. 2021;75:e14341.
  17. Peffault de Latour R, et al. Semin Hematol. 2022;59:38–46.
  18. Shah N, et al. Paroxysmal Nocturnal Hemoglobinuria. Available at: https://www.ncbi.nlm.nih.gov/books/NBK562292/#:~:text=Epidemiology,to%2099%20years.%5B2%5D. Accessed July 2025.
  19. Arnold LM, et al. Blood. 2008;112:4671.
  20. Bril V, et al. J Comp Eff Res. 2024;13:e230171.
  21. Teriou L, et al. EHA 2023; poster presentation [abs P783].
  22. Araten D, et al. Blood. 2024;144:3706–3707.
  23. Food and Drug Administration. PiaSky (crovalimab-akkz) new drug application integrated review. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761388Orig1s000IntegratedR.pdf. Accessed July 2025.